G
Gregory Kryukov
Researcher at Harvard University
Publications - 9
Citations - 4170
Gregory Kryukov is an academic researcher from Harvard University. The author has contributed to research in topics: HRAS & Cancer. The author has an hindex of 6, co-authored 9 publications receiving 3175 citations. Previous affiliations of Gregory Kryukov include Broad Institute.
Papers
More filters
Journal ArticleDOI
The Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Nicolas Stransky,Ann Marie Egloff,Aaron D. Tward,Aaron D. Tward,Aaron D. Tward,Aleksandar Kostic,Aleksandar Kostic,Kristian Cibulskis,Andrey Sivachenko,Gregory Kryukov,Gregory Kryukov,Michael S. Lawrence,Carrie Sougnez,Aaron McKenna,Erica Shefler,Alex H. Ramos,Petar Stojanov,Scott L. Carter,Douglas Voet,Maria L. Cortes,Daniel Auclair,Michael F. Berger,Gordon Saksena,Candace Guiducci,Robert C. Onofrio,Melissa Parkin,Marjorie Romkes,Joel L. Weissfeld,Raja R. Seethala,Lin Wang,Claudia Rangel-Escareño,Juan Carlos Fernández-López,Alfredo Hidalgo-Miranda,Jorge Melendez-Zajgla,Wendy Winckler,Kristin Ardlie,Stacey Gabriel,Matthew Meyerson,Eric S. Lander,Eric S. Lander,Eric S. Lander,Gad Getz,Todd R. Golub,Levi A. Garraway,Jennifer R. Grandis +44 more
TL;DR: In this article, the authors analyzed whole-exome sequencing data from 74 tumor-normal pairs and found that at least 30% of cases harbored mutations in genes that regulate squamous differentiation (for example, NOTCH1, IRF6, and TP63), implicating its dysregulation as a major driver of HNSCC carcinogenesis.
Journal ArticleDOI
Defining a Cancer Dependency Map
Aviad Tsherniak,Francisca Vazquez,Francisca Vazquez,Phil Montgomery,Barbara A. Weir,Barbara A. Weir,Gregory Kryukov,Gregory Kryukov,Glenn S. Cowley,Stanley Gill,Stanley Gill,William F. Harrington,Sasha Pantel,John M. Krill-Burger,Robin M. Meyers,Levi D. Ali,Amy Goodale,Yenarae Lee,Guozhi Jiang,Jessica Hsiao,William F.J Gerath,Sara Howell,Erin Merkel,Mahmoud Ghandi,Levi A. Garraway,David E. Root,Todd R. Golub,Jesse S. Boehm,William C. Hahn +28 more
TL;DR: DEMETER, an analytical framework that segregates on- from off-target effects of RNAi, demonstrates the basis behind one such predictive model linking hypermethylation of the UBB ubiquitin gene to a dependency on UBC and provides a foundation for a cancer dependency map that facilitates the prioritization of therapeutic targets.
Journal Article
The Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Nicolas Stransky,Ann Marie Egloff,Aaron D. Tward,Aleksandar Kostic,Kristian Cibulskis,Andrey Sivachenko,Gregory Kryukov,Michael S. Lawrence,Carrie Sougnez,Aaron McKenna,Erica Shefler,Alex H. Ramos,Petar Stojanov,Scott L. Carter,Douglas Voet,Maria L. Cortes,Daniel Auclair,Michael F. Berger,Gordon Saksena,Candace Guiducci,Robert C. Onofrio,Melissa Parkin,Marjorie Romkes,Joel L. Weissfeld,Raja R. Seethala,Lin Wang,Claudia Rangel-Escareño,Juan Carlos Fernández-López,Alfredo Hidalgo-Miranda,Jorge Melendez-Zajgla,Wendy Winckler,Kristin Ardlie,Stacey Gabriel,Matthew Meyerson,Eric S. Lander,Gad Getz,Todd R. Golub,Levi A. Garraway,Jennifer R. Grandis +38 more
TL;DR: The results indicate the ability of large-scale sequencing to reveal fundamental tumorigenic mechanisms and suggest the development of targeted therapies for head and neck cancer may be hindered by complex mutational profiles.
Journal ArticleDOI
Widely distributed noncoding purifying selection in the human genome
Saurabh Asthana,William Stafford Noble,Gregory Kryukov,Charles E. Grant,Shamil R. Sunyaev,John A. Stamatoyannopoulos +5 more
TL;DR: It is shown that a substantial fraction of active purifying selection in human noncoding sequences occurs outside of CNSs and is diffusely distributed across the genome, suggesting the existence of a large complement of humannoncoding variants that may impact gene expression and phenotypic traits.
Patent
Selective treatment of prmt5 dependent cancer
TL;DR: In this article, the authors proposed a method for identifying and treating PRMT5-related diseases in subjects or tissues which have an MTAP deficiency, alone or in combination, with a second agent that reduces MTAP activity and/or increases intracellular MTA levels.